'For
the quarter ending March 2024, consolidated net sales (including other operating income) of Cipla has increased 7.39% to Rs 6163.24 crore compared to quarter ended March 2023. Sales of Phamaceuticals segment has gone up 8.31% to Rs 5,996.38 crore (accounting for 96.57% of total sales). Sales of New Ventures segment has gone down 8.91% to Rs 212.99 crore (accounting for 3.43% of total sales). Inter-segment sales rose Rs 30.89 crore to Rs 46.13 crore. Profit before interest, tax and other unallocable items (PBIT) has jumped 32.71% to Rs 1,276.85 crore. PBIT of Phamaceuticals segment rose 30.35% to Rs 1,322.45 crore (accounting for 103.57% of total PBIT). PBIT of New Ventures segment rose 13.01% to Rs -45.60 crore (accounting for -3.57% of total PBIT).
PBIT margin of Phamaceuticals segment rose from 18.33% to 22.05%. PBIT margin of New Ventures segment rose from negative 22.42% t...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Aug-2024)
AIA Engineering
Net down 5% on lower sales
-
(17-Aug-2024)
Voltas
Net jump 159% on good operating show
-
(17-Aug-2024)
ABB India
Net up 50% on good operating show
-
(17-Aug-2024)
NHPC
Sales down 2%, net down 1%
|
|